Rimonabant reveals reward- and anxiety-related behavioral effects of N-arachidonoyl dopamine (N-ADA) in mice.
It is indicated that prior exposure to N-ADA can influence reward- and anxiety-related behaviors specifically under conditions of CB1 blockade/GPR55 modulation and an interaction with endocannabinoid signaling (or other rimonabant-sensitive mechanisms) is indicated.